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Abstract
Background: Small invertebrate animals, such as nematodes and fruit flies, are increasingly being used to test candidate
drugs both for specific therapeutic purposes and for long-term health effects. Some of the protocols used in these
experiments feature such experimental design features as lifelong virginity and very low densities. By contrast, the ability of
both fruit flies and nematodes to resist stress is frequently correlated with their longevity and other functional measures,
suggesting that low-stress assays are not necessarily the only useful protocol for testing the long-term effects of drugs.
Methodology/Principal Findings: Here we report an alternative protocol for fruit fly drug-testing that maximizes
reproductive opportunities and other types of interaction, with moderately high population densities. We validate this
protocol using two types of experimental tests: 1. We show that this protocol detects previously well-established genetic
differences between outbred fruit fly populations. 2. We show that this protocol is able to distinguish among the long-term
effects of similar types of drugs within two broad categories, stimulants and tranquilizers.
Conclusions: Large-scale fly drug testing can be conducted using mixed-sex high-density cage assays. We find that the
commonly-used stimulants caffeine and theobromine differ dramatically in their chronic functional effects, theobromine
being more benign. Likewise, we find that two generic pharmaceutical tranquilizers, lithium carbonate and valproic acid,
differ dramatically in their chronic effects, lithium being more benign. However, these findings do not necessarily apply to
human subjects, and we thus do not recommend the use of any one substance over any other.
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Introduction
A widespread pharmacological practice is to take a medication
for a short period in order to stop a bacterial infection or relieve a
symptom, such as pain. But it is now also common for patients to
ingest pharmacologically-active substances for decades, whether as
long-term prescribed medications, such as statins, or as over-the-
counter (OTC) substances for which no prescription is needed,
such as aspirin. Of particular significance are substances, or
agents, that act on the central nervous system (CNS) and are taken
for years or decades on a sustained basis, on the basis of a doctor’s
prescription, in response to medical advice, or, perhaps most often,
to self-medicate.
Some of these CNS agents, such as ethanol, have long-term
functional effects that are well-documented [1,2]. Ethanol is well-
known for its impairment of cognition and judgment, and also for
its beneficial effects on cardiovascular disease at moderate regular
doses [3]. But at sustained high doses, ethanol has health risks
associated with its effects on liver function, lipids, coronary heart
disease, hypertension, stroke, diabetes, dementia, and cancer
progression [4,5,6]. In terms of aggregate effects on all-cause
mortality, ethanol shows a J-shaped pattern, with overall beneficial
effects on mortality at moderate consumption levels, even
compared with complete abstention, yet overall deleterious effects
at high levels of consumption [6]. The data that underlie this
conclusion have been decades in the collection; early publications
date back to the 1920s.
The problem is that the long-term effects of many other CNS
agents remain unclear. For example, the relationship between
coffee consumption and aggregate mortality is still unclear, despite
decades of human studies [7]. A complicating factor is that the
effects of coffee consumption on the mortality rates of human
subjects are non-linear, sometimes gender-dependent, and appar-
ently affected by caffeine content in a complex, sometimes
ambiguous, manner.
One solution to the dilemma raised by the long-term side-effects
of chronically consumed CNS agents is to study their effects in
model animal species, for which regular dosing and prospective
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relatively feasible, at least compared with research on human
subjects [8,9]. However, there are problems with such studies. Of
particular recent note has been the problematic status of the
substance resveratrol in animal model studies. Despite promising
early reports of its efficacy in several model species [10], it has
proven difficult to reproduce those early results in other studies of
some of these same species [11].
Life-long cohort studies of animal model species face a number
of pertinent difficulties with respect to execution, analysis, and
interpretation that are inherent to the use of such model species
studies. The most obvious difficulty is that such animal model
species are not biochemically equivalent to human subjects.
However, this difficulty has been greatly alleviated with the
discovery of the genomic commonalities between humans and
bilaterian animal species with respect to key pathophysiological
pathways [12,13,14]. There is a common genetic toolkit that is
largely shared between humans and these model species, contrary
to many preconceptions that were common for much of the 20
th
Century, a surprising biological fact that has transformed
biological research [15].
But there are a number of less obvious difficulties with life-long
cohort testing that have not been resolved by the promising
molecular commonality among animal species. Many of these
difficulties have been reviewed in detail by Jafari and Rose [16],
and we will only briefly reiterate a few key points here, as they will
prove important in the interpretation of our results. It is important
that model cohort studies should not employ animals that are
greatly sickened either by genetic impairments, such as those
produced by inbreeding and mutagenesis, or by poor experimental
conditions, such as conditions in which it is difficult for animals to
derive sufficient nutrition. While it might seem as if this
requirement can be readily addressed simply by monitoring
average longevities, this is in fact not the case.
A model organism that has been genetically sterilized or given
very poor conditions can live longer because of beneficial effects of
reduced reproductive activity on survival [17]. Thus a substance
that is administered in an animal’s food throughout their adult
lives may reduce its reproductive rate, and thereby increase its
lifespan through a reduction in the physiologically costly effect of
reproduction on survival. That is, some substances may have an
ostensibly beneficial effect, when only longevity or mortality-rates
are monitored, an effect that can be an artifact of functional
impairment of reproductive characters, characters that are often
not observed in drug studies that consider only survival rates or
longevity. Thus average longevity, on its own, may be a poor
measure of the full spectrum of harmful effects of administered
substances. In particular, to take an extreme case, a drug that
sterilizes an invertebrate model organism, but thereby significantly
increases its longevity, might be erroneously considered beneficial.
That this is not a hypothetical problem is illustrated well by the
copious data on dietary restriction in model organisms: it is well-
known that animal cohorts which receive fewer nutrients can
exhibit an increase in average lifespan in conjunction with reduced
fertility [18]. Chronic ‘‘medication’’ of an experimental cohort
could have a seemingly beneficial effect if it merely reduces
nutritional intake due to a perceived noxiousness of this
‘‘medication’’ for the model organism. Or an animal might be
rendered so lethargic by a substance that its feeding rate is reduced
along with other appetitive behaviors, the reduced food intake
leading to reduced reproduction, with a secondary beneficial effect
on longevity.
Thus it is very important for studies that use model organisms to
monitor the long-term side-effects of medications on functional
characters as well as aggregate measures of mortality, such as
average or maximum longevity. In the present study, we present a
new type of assay for the long-term effects of candidate
medications, one that features a mixed-sex regime at moderate
densities. In order to validate this experimental design, we
performed two types of experiments.
First, we compared the mortality patterns exhibited by two well-
known sets of Drosophila melanogaster populations that have long
been shown to exhibit strikingly differentiated patterns of survival:
the ‘‘B’’ and ‘‘O’’ populations long studied by Rose and his
colleagues [19]. Our view was that any useful assay should
replicate the much greater longevities of O flies compared to B
flies.
Second, we used this assay method in studies of the chronic side-
effects of four CNS agents: caffeine, theobromine, lithium
carbonate, and valproic acid. These four agents were chosen as
two complementary pairs. The first two are non-pharmaceutical
stimulants which are commonly used by adults over their entire
lifetime, caffeine being the chief stimulant found in coffee and tea,
although it is also present in chocolate, while theobromine is the
other key alkaloid stimulant found in chocolate. Caffeine and
theobromine are similar to each other biochemically, and both are
commonly perceived as ‘‘stimulants.’’ The second two CNS
agents, lithium carbonate and valproic acid, are pharmaceutical
sedatives which are prescribed for use as maintenance prophylactic
medications for patients who have been diagnosed with bipolar
disease, epilepsy, and a variety of related conditions. The
conventional medical interpretation of their action is that they
function to suppress inappropriately high level of neurological
activation, although this is only a crude characterization of their
complex biochemical effects [20]. Both are often taken for
decades. Our view was that our assay, if valid, should be capable
of revealing contrasting dose-dependent effects of these substances
on lifespan and other functional characters.
Results
Basic Assay Protocols
Mortality. Stocks of D. melanogaster were cultured in vials with
normal banana medium at about 25 degrees Celsius, as in
previous assays conducted by the Rose laboratory [21]. The flies
were transferred to Plexiglas cages at 14 days of age from egg and
kept through adulthood at the same ambient temperature. Once in
the cages, the flies were fed banana medium supplemented with
yeast paste. The Petri dishes were changed daily until all the flies
were dead.
Mating. One virgin female and two competing males, one
‘‘control’’ and one ‘‘treated,’’ were placed together in a single glass
vial. Half of the treated males and half of the control males were
marked with a black marker at the distal end of their right wing.
The flies were given two hours in which to mate.
Fecundity. Laying vials were one-quarter full of charcoal
agar media, with one female and one male. The number of eggs
laid after one day in the vials was counted and recorded.
See the Methods and Materials for more detail.
Using the Cage Assay to compare B and O demography
Demography of B and O populations. For flies derived
from each of the five B and five O populations, four separate cage
cohorts were used to estimate longevity and mortality rates. Each
of these cohorts had very close to 750 individuals per sex, for a
total of about 1,500 individuals of both sexes per cage. Thus the
total number of sex-specific and cage-specific cohorts was 80. D.
melanogaster mortality reaches a plateau at advanced ages [19,22],
Side-Effects in D. melanogaster
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enough to show these plateaus. Accordingly, we restricted our
analysis of the individual cohorts to the Gompertz equation [23]:
Aexp(ax), where A is the age-independent rate of mortality and a is
the age-dependent rate of mortality increase. The parameters A
and a were estimated by maximum likelihood (see Methods
section).
The pooled natural log of mortality for the B and O populations
shows no evidence of a plateau (figure 1). In fact, in Figure 1 the O
mortality rates appear to accelerate at advanced ages, rather than
level off. This indicates a temporal change in the cage
environment that is affecting mortality, an effect that is not
unexpected, because the cage environment was not cleaned during
the course of the assays. Providing a new clean cage to a cohort of
adult flies can require anesthetizing the entire cohort, a procedure
that places them at risk of suffocating if their spiracles become
clogged with medium or other material when they are immobile.
For this reason, we wanted to conduct our adult mortality trials
using the same cage throughout. This design choice led to visible
accumulation of material on the walls of cages, much of this
material being fly excreta. We thus expected to find some evidence
for increased mortality resulting from the adverse effects of the
deteriorating environment in the cages. To test this idea, we fit the
Gompertz equation to the mortality observations and then
computed the difference between the observed mortality and the
predicted mortality rate (Figure 2). At later ages, the observed
mortality rates become and remain larger than the Gompertz-
predicted mortality. Our interpretation is that the O cage
environment was becoming progressively fouled over the course
of the assay, while the B flies died long before they produced such
a significant fouling effect.
An analysis of the 80 values of A and a from the Gompertz
equation showed no significant effect of sex on these values. A
model that just included the distinct population types (i.e. B vs. O)
as a fixed factor and the random factors of population and cage
yielded a highly significant effect of selection regime on A
(p=4 610
27) and a (p=5 610
29). There is no overlap between
the B and O populations in the estimated values of these two
parameters (figure 3). Population variation, such as variation
among the five different B populations, contributes about 21–26%
of the total variation in the two Gompertz parameters. Cage
variation makes a much smaller contribution, about 1.6% of the
variation in A and virtually none of the variation in a.
Comparisons of CNS Drugs
All drug studies were conducted using flies derived from the B
populations used in the previous study, a set of populations
originally founded in 1980, and never systematically inbred [21].
We find that each of the two pairs of CNS agents studied here
show strikingly different side-effects on mortality when taken
throughout adult life, despite their ostensible similarities within
each pair with respect to their impact on CNS functions, as either
stimulants or sedatives. These findings suggest that studies of the
long-term side-effects of pharmacological agents in model species
may be of value particularly in revealing the potential complexity
of the effects that these agents might have on chronic human
Figure 1. The natural log of age specific mortality in the B and
O cohorts. Data of cohorts from of all populations and sexes have
been combined in this figure. In total the B-mortality rates are based on
30,055 individuals and the O mortality rates are based on 29,372
individuals.
doi:10.1371/journal.pone.0006578.g001
Figure 2. The differences between the observed mortality of
the O-cohorts and the predicted Gompertz mortality (circles).
The lines above and below the symbols are the binomial 95%
confidence limits for the observed mortality.
doi:10.1371/journal.pone.0006578.g002
Figure 3. The distribution of A and a values for the B and O
cohorts. Each symbol is data from one gender from a single
population cage, e.g. males of the fourth cage of B1 flies. There are
eight similar symbols representing each of the four cages and two
sexes, for a total of 80 data points.
doi:10.1371/journal.pone.0006578.g003
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agents on human subjects are necessarily disclosed by studies of
model organisms.
Mortality. The mean longevity is either statistically equivalent
to or statistically lower than that at the control level for caffeine
(Figure 4, table 1), theobromine (Figure 5, table 1), and valproic acid
(Figure 6, table 1), but not lithium carbonate (Figure 7, table 1). At
the two lowest doses of lithium, there is a slight elevation in mean
longevity. An examination of age-specific mortality shows that
lithiumlowersbothparametersofthe Gompertzequation (table 2)at
the two lowest doses, and the beneficial effects on the age-dependent
parameter are statistically significant at the intermediate dose. The
other compounds (tables 3–4, 5) typically increase one or both
Gompertz parameters, leading to increased mortality rates. There
are a few exceptions. Theobromine (table 3) and caffeine (table 5)
significantly decrease the age-dependent Gompertz parameter but
significantly increase the age-independent Gompertz parameter.
These two effects work in opposite directions, and thus the
longevities of flies at the lowest doses of theobromine and caffeine
are about the same as that of the controls.
Female fecundity. Typically these compounds all have drastic
effects on female fecundity in this study (figure 8, tables 6–9). The
one exception is theobromine (table 8), which does not significantly
lower fecundity at the lowest dose. Any potential enthusiasm
concerning thepotentiallifeextendingabilityof lithium isdampened
by the significant negative impact of this drug on fecundity (table 9).
Female fecundity shows a significant drop with age (e.g. k is
significant ineverycase,tables6–9).Thisisofcourseexpecteddueto
the normal effects of aging on this life-history trait. Somewhat
paradoxically, the age-by-dose interactions often show significant
positive effects, suggesting that the drop in fecundity with age is not
as large as expected at later ages with some substances. This effect
may simply reflect the fact that at young ages these agents have
alreadyloweredfecunditysomuchthat itdropsrelatively littleatlate
ages, perhaps reflecting an ‘‘egg-hoarding’’ pattern.
Male mating. All tests for the effects of our marking
technique on mating were non-significant, so the results of our
tests for marking effects are not included in our table of results.
Almost all substances and all doses significantly lower the mating
success of males (table 10), the one exception being theobromine,
which is not significantly different from controls at the two lowest
doses (table 10). There is also very often a significant age by dose
interaction (table 10). This interaction indicates that these
substances tend to make male performance relatively worse at
old age, the opposite of the effect on female fecundity.
Figure 4. The daily mortality rates for B flies receiving a range
of doses of caffeine, with a linear scale for the mortality rates.
The dose levels are color-coded: black line and points, control data;
yellow line and points, 10% of the estimated normal human dose; red
line and points, the estimated human dose; blue line and points, 10
times the estimated human dose.
doi:10.1371/journal.pone.0006578.g004
Table 1. Mean longevity (days) of adults flies receiving
different doses of lithium, valproic acid, theobromine, caffeine
and their controls.
Drug Dose Mean (Days) Standard Error
Lithium
10 11.1 0.12
1 14.6 0.15
0.1 15.2 0.11
Control 13.4 0.31
Valproic Acid
10 8.2 0.06
1 11.3 0.15
0.1 10.2 0.15
Control 12.4 0.15
Theobromine
10 10.6 0.14
1 12.1 0.44
0.1 11.4 0.2
Control 12.2 0.38
Caffeine
10 11.1 0.39
1 12.2 0.88
0.1 17.9 0.78
Control 12.2 0.38
doi:10.1371/journal.pone.0006578.t001
Figure 5. The daily mortality rates for B flies receiving a range
of doses of theobromine, with a linear scale for the mortality
rates. The dose levels are color-coded: black line and points, control
data; yellow line and points, 10% of the estimated normal human dose;
red line and points, the estimated human dose; blue line and points, 10
times the estimated human dose.
doi:10.1371/journal.pone.0006578.g005
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We address three issues in our discussion: (i) validity of the assay
protocols that we have used; (ii) interpretation of the specific results
for the substances that we have tested here; and (iii) general
questions concerning the use of model systems for testing the
chronic effects of substances that are used medically or
recreationally for long periods by human subjects.
Protocol Validity
Two features of the survival data were surprising for us. First,
average longevities were quite low. Second, our data do not show
detectable late life plateaus, a ubiquitous observation in studies of
sufficiently large Drosophila cohorts [19,22], including cohorts of
the laboratory populations used here.
Our analysis of the low longevities starts with the premise that a
valid survival assay should preserve the clear differences observed
in prior studies comparing B and O cohorts. In some respects, the
experiment comparing B and O populations confirmed that our
protocols were valid: average longevities and estimated Gompertz
parameters were all strikingly different (see Figures 1 and 3), as
observed in the earlier studies. Thus our cage assays were capable
of appropriately detecting differences in cohort aging patterns.
The anomaly in this extensive experimental comparison is the
absence of the late-life mortality rate plateaus previously observed
for these populations [19]. Figure 2 reveals why this may have
occurred in the case of the long-lived O populations, which on
average live more than four times longer than the B populations:
our cage environments become progressively more subject to
Figure 7. The daily mortality rates for B flies receiving a range
of doses of xxxxx, with a linear scale for the mortality rates. The
dose levels are color-coded: black line and points, control data; yellow
line and points, 10% of the estimated normal human dose; red line and
points, the estimated human dose; blue line and points, 10 times the
estimated human dose.
doi:10.1371/journal.pone.0006578.g007
Table 2. Gompertz parameter estimates for lithium.
Parameter drug dose Value Std.Error DF t-value p-value
Components of the age-independent Gompertz parameter, A
p1 24E205 2.2E205 482 21.7 0.083
b1 control 0.0447 0.0015 482 3 0.0028
c11 0.1 0.0062 0.0057 482 1.1 0.028
c12 1 0.007 0.0051 482 1.4 0.17
c13 10 0.0311 0.0055 482 5.7 ,0.0001
Components of the age-independent Gompertz parameter, a
p2 8.2E205 7.2E205 482 1.1 0.26
b2 control 0.0804 0.0048 482 1.7 0.098
c21 0.1 20.0359 0.02 482 21.8 0.073
c22 1 20.0365 0.018 482 22 0.042
c23 10 20.064 0.016 482 23.9 0.0001
Drug doses that are significantly different from the control have bold p-values.
The parameters are from equation (4) and indicate the following effects: density
(p), controls (b), drug levels (c).
doi:10.1371/journal.pone.0006578.t002
Figure 6. The daily mortality rates for B flies receiving a range
of doses of xxxxx, with a linear scale for the mortality rates. The
dose levels are color-coded: black line and points, control data; yellow
line and points, 10% of the estimated normal human dose; red line and
points, the estimated human dose; blue line and points, 10 times the
estimated human dose.
doi:10.1371/journal.pone.0006578.g006
Table 3. Gompertz parameter estimates for theobromine.
Parameter drug dose Value Std.Error DF t-value p-value
Components of the age-independent Gompertz parameter, A
p1 20.0001 3E205 476 24.5 ,0.0001
b1 control 0.114 0.017 476 6.7 ,0.0001
c11 0.1 0.0325 0.0061 476 5.3 ,0.0001
c12 1 20.026 0.0068 476 0.38 0.7
c13 10 0.0241 0.006 476 4 0.0001
Components of the age-independent Gompertz parameter, a
p2 0.0003 6E205 476 5.2 ,0.0001
b2 control 20.109 0.038 476 22.9 0.0041
c21 0.1 20.065 0.013 476 25.1 0.03
c22 1 20.0205 0.013 476 21.6 0.11
c23 10 20.0336 0.011 476 23.1 0.0023
Drug doses that are significantly different from the control have bold p-values.
The parameters are from equation (4) and indicate the following effects: density
(p), controls (b), drug levels (c).
doi:10.1371/journal.pone.0006578.t003
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unreliable after the age of 80 days of adult life. However, none of
our experimental tests of CNS agents involved flies surviving that
long, so this contamination or ‘‘fouling’’ process probably did not
affect our data with the B flies.
Therefore, this fouling effect does not explain the absence of a
detectable late-life mortality plateau in the shorter lived B cohorts.
Our explanation for this B cohort result is that the baseline
mortality level, the A Gompertz parameter, in the present
experiment is so high that not enough B flies survive long enough
to reach late life. In the vial protocol used in earlier studies [19],
late-life mortality plateaus were readily observed in the same type
of populations as those used in the present study. But those flies
lived much longer, with average longevities of more than 20 days,
and average A parameters of 0.0034 and 0.0054 in males and
females, respectively. In the present study, our controls averaged
about 70 per cent of the longevities found previously [19], while
the average A parameters were three to five times higher. In the
cage environment, then, almost all the B flies don’t live long
enough to enter the post-aging phase. This, in several respects,
makes the present cage assay protocol preferable for studies of
aging specifically, in that late-life effects will have little impact on
our data, rendering a Gompertz analysis relatively more reliable,
at least up until the age of 80 days, when cage fouling becomes
important. However, normal-lived flies will almost never survive
that long. Thus we conclude that the assay methods of the present
study were appropriate for substance testing with normal, as
opposed to exceptionally long-lived, flies.
Interpretation of the substance testing results
Lithium carbonate. Previous studies of the impact of lithium
on aging in model organisms found a beneficial effect on longevity
Table 4. Gompertz parameter estimates for valproic acid.
Parameter drug dose Value Std.Error DF t-value p-value
Components of the age-independent Gompertz parameter, A
p1 5E206 4E205 189 0.15 0.88
b1 control 0.0282 0.023 189 1.2 0.22
c11 0.1 20.007 0.0038 189 22.5 0.014
p1 3E205 2E205 197 1 0.3
b1 control 0.0157 0.016 197 1 0.32
c12 1 20.014 0.0043 197 23.5 0.0007
p1 22E205 8E205 184 20.31 0.75
b1 control 0.0446 0.052 184 0.86 0.39
c13 10 0.0328 0.0187 184 1.8 0.08
Components of the age-independent Gompertz parameter, a
p2 7E206 0.0001 189 0.07 0.94
b2 control 0.0989 0.064 189 1.5 0.12
c21 0.1 0.0772 0.012 189 6.6 ,0.0001
p2 26E205 8E205 197 20.75 0.46
b2 control 0.143 0.0054 197 2.7 0.0085
c22 1 0.0784 0.015 197 5.3 ,0.0001
p2 6E205 0.0002 184 0.36 0.72
b2 control 0.0722 0.11 184 0.67 0.51
c23 10 0.094 0.038 184 0.25 0.81
Drug doses that are significantly different from the control have bold p-values.
The parameters are from equation (4) and indicate the following effects: density
(p), controls (b), drug levels (c).
doi:10.1371/journal.pone.0006578.t004
Table 5. Gompertz parameter estimates for caffeine.
Parameter drug dose Value Std.Error DF t-value p-value
Components of the age-independent Gompertz parameter, A
p1 20.000036 0.0000038 538 29.3 ,0.0001
b1 control 0.0601 0.0048 538 12.6 ,0.0001
c11 0.1 0.0131 0.0013 538 10.1 ,0.0001
c12 1 0.056 0.0035 538 16.1 ,0.0001
c13 10 0.0339 0.0037 538 9.2 ,0.0001
Components of the age-independent Gompertz parameter, a
p2 0.000021 0.000017 538 1.2 0.22
b2 control 0.0583 0.021 538 2.8 0.005
c21 0.1 20.0147 0.0072 538 22 0.041
c22 1 20.035 0.011 538 23.2 0.0012
c23 10 0.0113 0.013 538 0.9 0.37
Drug doses that are significantly different from the control have bold p-values.
The parameters are from equation (4) and indicate the following effects: density
(p), controls (b), drug levels (c).
doi:10.1371/journal.pone.0006578.t005
Figure 8. The mean fecundity of females receiving varying
doses of the four drugs at two ages. The controls were maintained
on normal food.
doi:10.1371/journal.pone.0006578.g008
Table 6. The effects of valproic acid on female fecundity.
Parameters Drug dose Estimate Std. Error t value Pr(.|t|)
c control 7.69 0.071 108.2 ,2610
216
a1 0.1 24.51 0.1 244.9 ,2610
216
a2 1 25.03 0.1 250.1 ,2610
216
a3 10 25.56 0.1 255.3 ,2610
216
k control 22.6 0.174 215 ,2610
216
b1 0.1 0.579 0.246 2.35 0.019
b2 1 0.785 0.246 3.19 0.0015
b3 10 0.858 0.246 3.49 0.00054
The parameter values are from equation (9).
doi:10.1371/journal.pone.0006578.t006
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result here, together with progression to toxicity at higher levels of
lithium. We were not surprised to find evidence for depressed male
mating success and female fecundity with this substance, since it is
well-known for its broadly ‘‘sedative’’ effects in the psychiatric
literature, being a potent anti-manic agent [25]. As such, lithium
provides a useful baseline that helps further validate the protocols
that we have employed in this study.
Valproic acid. Valproic acid provides an interesting contrast
with lithium carbonate. Both substances are know for their
depressive effects on CNS function, and both are long-standing
drugs of choice for mania, with valproic acid also in widespread use
as an anti-seizure medication [26]. In keeping with such medical
uses, valproic acid has broadly depressive effects on both male
mating success and female fecundity in this study. Like moderate
doses of lithium, moderate dosing of Drosophila with valproic acid
reduces these two measures of functional fruit fly activity. By
contrast, however, valproic acid in the formulation that we have
used strikingly reduces lifespan at moderate doses, calibrated to the
same dose/unit mass scale as lithium, as shown in Figure 5. Even at
a dose that we estimate as equivalent to one-tenth the normal
human dose, longevity is strikingly reduced, compared to both
control longevity and longevity at the corresponding lithium dose.
This is a marked disparity, which we discuss further below.
Caffeine. With caffeine, we were expecting the opposite effects
on functional characters from those observed with lithium and
valproic acid. That is, we expected caffeine to increase early male
mating success and early female fecundity, with possible reductions
in these characters later inlife. We made this assumption because we
expected caffeine to stimulate biological activity in Drosophila.T h i s
expectation was not met, and caffeine was instead generally an
antagonist for the functions we tested. In addition, caffeine was
clearly detrimental to survival. It was quite surprising to us to find
thatcaffeinewassucha toxicsubstance,atleastatdose-levelsthat we
estimate to correspond to normal human intake, in that caffeine has
been tested for insecticidal activity and none has been found [27].
Theobromine. Like caffeine, and again contrary to our
expectations, theobromine did not enhance functional activity in
our flies. But, despite its biochemical and functional similarities to
caffeine, theobromine was the most benign of all the substances
that we tested, even at doses that we estimated to correspond to
normal human levels of consumption. While there is a dose-
dependent reduction in function, the effect of theobromine on
both function and longevity is small relative to the effects of the
three other substances that we report on here.
Validity of using model species to test for chronic effects
Naturally, the point of greatest interest for studies of the present
kind is the light that they may, or may not, shed on substances
Table 7. The effects of caffeine on female fecundity.
Parameters Drug dose Estimate Std. Error t value Pr(.|t|)
c Control 7.69 0.0725 106.1 ,2610
216
a1 0.1 25.06 0.102 249.3 ,2610
216
a2 1 25.23 0.102 251.1 ,2610
216
a3 10 25.59 0.102 254.6 ,2610
216
k Control 22.33 0.177 213.2 ,2610
216
b1 0.1 0.916 0.251 3.65 0.0003
b2 1 0.376 0.251 1.5 0.13
b3 10 0.727 0.251 2.9 0.003999
The parameter values are from equation (9).
doi:10.1371/journal.pone.0006578.t007
Table 8. The effects of theobromine on female fecundity.
Parameters Drug dose Estimate Std. Error t value Pr(.|t|)
c Control 8.13 0.0869 93.6 ,2610
216
a1 0.1 20.171 0.123 21.39 0.16
a2 1 20.442 0.123 23.6 0.00037
a3 10 20.736 0.123 25.99 4.93610
29
k Control 22.6 0.213 212.2 ,2610
216
b1 0.1 20.0187 0.301 20.062 0.95
b2 1 20.4 0.301 21.33 0.19
b3 10 21.89 0.301 26.29 8.81610
210
The parameter values are from equation (9).
doi:10.1371/journal.pone.0006578.t008
Table 9. The effects of lithium on female fecundity.
Parameters Drug dose Estimate Std. Error t value Pr(.|t|)
c Control 8.13 0.0613 132.5 ,2610
216
a1 0.1 25.61 0.0867 264.7 ,2610
216
a2 1 25.69 0.0867 265.6 ,2610
216
a3 10 26.65 0.0867 276.6 ,2610
216
k Control 22.6 0.15 217.3 ,2610
216
b1 0.1 1.36 0.212 6.42 4.11610
210
b2 1 0.893 0.212 4.2 3.32610
210
b3 10 1.61 0.212 7.57 2.91610
213
The parameter values are from equation (9).
doi:10.1371/journal.pone.0006578.t009
Table 10. The effects of CNS agents and age on male mating
preference.
Supplement Dose
Fraction mated
to control
p-value for
significance tests
early late dose dosage
Caffeine 10 0.78 1 ,0.00001 ,0.00001
1 0.75 0.97 ,0.00001 0.00001
0.1 0.68 0.86 ,0.00001 0.006
Valproic acid 10 0.75 1 ,0.00001 ,0.00001
1 0.73 1 ,0.00001 ,0.00001
0.1 0.7 1 ,0.00001 ,0.00001
Lithium 10 0.97 1 ,0.00001 0.11
1 0.88 0.97 ,0.00001 0.039
0.1 0.82 0.98 ,0.00001 0.0005
Theobromine 10 0.68 0.76 ,0.00001 0.38
1 0.59 0.54 0.01 0.71
0.1 0.51 0.43 0.56 0.42
doi:10.1371/journal.pone.0006578.t010
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conclusions.
There are material discrepancies within pharmacological
groupings. We find marked disparities in the effects of both
supposed sedatives and supposed stimulants. Despite the parallel
uses to which lithium and valproate are put, they have strikingly
contrasting effects on long-term survival, at least in Drosophila.
Likewise, caffeine and theobromine are both widely-used as
stimulants, the latter usually in conjunction with caffeine in
chocolate, yet in our tests caffeine proved to be strikingly toxic
compared to theobromine, particularly at high doses.
These results are reminiscent of those obtained by Jafari et al
[28] in their Drosophila studies of a group of pharmaceuticals used
to treat Type II diabetes. These substances differed markedly in
their chronic effects on mortality rates, some being significantly
beneficial in effects on mortality, along with some heterogeneity in
their effects on functional characters like those studied here.
Similarly, comparisons of a large number of antioxidant
substances revealed striking contrasts in their effects on aging in
C. elegans [29].
The overall pattern that all three studies disclose is marked
heterogeneity in the chronic impact of substances, at least among
model species, that have been grouped together pharmacological-
ly. Whatever intuitive notions that we might have about the
chronic effects of using drugs that are commonly grouped
together, such notions do not hold up when these chronic effects
are tested in model organisms. How far this heterogeneity might
extend is difficult to say. It is possible, for example, that slightly
different pharmacological preparations may have important
differences in their long-term effects on patients.
Functional effects may be more complex than
expected. Even though caffeine and theobromine are widely
used to enhance cognitive and athletic function, our results lead
us to question whether these agents have all of their expected
enhancing effects. For example, caffeine improves alertness and
some performance tests, but it can also suppress sperm count and
fertility [30,31,32]. The negative effects of caffeine on fertility
indicate that caffeine fails to enhance Nature’s most important
performance – generating viable progeny. Similarly, though it is
widely assumed that anti-oxidants are generally beneficial for
health, because of supposed universal hazards posed by free-
radical damage, the study of Lithgow and colleagues [29]
suggests that such benefits are not indeed as general as widely
supposed.
Use of model systems to test for chronic direct benefits
and side effects. Finally, we come to the question of whether
the use of model systems to undermine such general suppositions
about efficacy is warranted. Many of the supposed benefits of
agents like anti-oxidants or caloric restriction mimetics,
resveratrol being a famous example, are often first identified in
model organisms like Drosophilaand Caenorhabditis. To the extent to
which model organisms can be used to identify supposedly
beneficial substances for medical or other uses, they perforce must
also be of value in raising questions about the use of such agents,
questions that may be directed at either the supposed benefits of
such agents or their chronic side effects. The key value of
analyzing the effects of compounds on life span in a model system
like Drosophila is that long term functional effects on the whole
organism can be directly evaluated. While such model-organism
results should not be considered definitive in their implications for
medical or recreational substance use, they can serve to focus
attention on important side-effects of a chronically-used
substance, ideally leading to further directed preclinical and
clinical evaluation.
Materials and Methods
Experimental Procedures
Drug dosing: Three doses were used for each tested substance.
We centered our doses on a dose that was estimated by means of a
rough extrapolation from common human dosing. However, we
recognized the very approximate nature of these calculations and
therefore used flanking doses both ten times greater and ten times
less than our estimated human dose. Our estimated daily human
intake for each substance was as follows: 8 mg per kg body weight
for caffeine (citrated) (CAS number 69-22-7 from Professional
Compounding Centers of America), 13 mg/kg for lithium
carbonate (CAS number 554-13-2 from Spectrum Chemical
Mfg. Corporation), 12 mg/kg for theobromine (CAS number 83-
67-0 from Spectrum Chemical Mfg. Corporation), and 10 mg/kg
for valproic acid (CAS number 99-66-1 from Pharmaceutical
Associates, Inc.). To extrapolate dosing, we assumed a 75 kg
human and a 1 mg fly. These substances were added to yeast paste
which consisted of 5 gm dry yeast, 10 mL water, and 0.5 mL
acetic acid. One fourth of this yeast paste would be put on the
surface of a Petri dish full of standard fly food [21]. Food plates
were changed daily. We assumed that the adults would consume
an amount of this yeast equal to 5% of their body weight per day.
The ‘‘1.0’’ dose in this study corresponds to the approximate
human dose and the final compound concentrations in yeast were:
caffeine, 0.16 mg/gm yeast; lithium, 0.26 mg/gm; theobromine,
0.24 mg/gm; valproic acid, 0.20 mg/gm. The ‘‘10’’ dose was ten
times these concentrations and the ‘‘0.1’’ dose was one-tenth of
these concentrations.
Mortality. Stocks of Drosophila melanogaster were cultured in
polystyrene vials one quarter full of banana agar medium at an
ambient temperature of 25 degrees Celsius. The flies were
transferred to Plexiglas cages at 14 days of age from egg and
kept through adulthood at the same ambient temperature. The
cages were custom made by Plastic Sales, Inc. in Costa Mesa, CA.
The cages are made of 0.5 cm thick Plexiglas sheets sealed
together with epoxy. The cages are 25 cm long, 20 cm wide and
14 cm high. On either side of the 7.5 cm by 12.5 cm opening of
the cage, there is a screw with the head inside the cage and the end
sticking out. A polyester sleeve with two open ends is attached to
the screws through buttonholes in the seam. Another sheet of
Plexiglas that that looks like a picture frame, measures 20 cm by
14 cm, and has a 7.5 cm by 12.5 cm opening for the cage and two
holes for the screw ends is slid over the sleeve with the opening of
the sleeve passing through the opening of the picture frame piece.
This piece is held in place by two wing nuts that are screwed onto
the screw ends that hold together the cage, the sleeve, and the
picture frame piece. The end of the sleeve is tied in a simple knot
and the flies cannot escape. Once in the cages, the flies were fed
156100 mm Petri dishes full of banana agar medium with the
surface covered in yeast paste that consists of dry yeast, acetic acid,
water. In the non control cages, the yeast paste contained the
assigned dosage (10, 1, 0.1 ml) of one of 4 substances: caffeine
citrate, valproic acid, lithium, and theobromine. The Petri dishes
were changed daily until all the flies were dead.
When fly cohorts are maintained in population cages of the
design that we used, eggs laid away from the food medium fail to
develop successfully, while the food medium is removed
sufficiently often that development cannot be completed when
the eggs are laid there. Furthermore, the pupal stage required to
complete development is of sufficient duration to make the
detection of successful offspring development easy to detect; no
such pupal development was detected in the course of these
experiments.
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substances, including two sets of four control cages. Each cage
contained between 1,300 and 2,500 young, mature fruit flies of the
species D. melanogaster. Every day we supplied the cages with new
Petri dishes of banana agar media, each covered in yeast paste
containing the assigned substance in the assigned quantity for each
cage. At this time, we counted and recorded the number of dead
flies in each cage. The dead flies were removed from the cages
using an aspirator. After aspiration of the dead flies from the cage,
the collected flies were emptied onto a paper towel where they
were counted and sexed. Male flies are identified by the presence
of sex combs on the forelegs and female flies are identified by their
larger, striped abdomens and the absence of the sex combs. The
numbers of dead males and females were recorded in a bound
notebook. It is estimated that no more than five flies per day died
or escaped as a result of handling procedures. These flies were not
recorded in the notebook because they did not die as a result of
ingestion of their assigned substance. The above procedure
continued until all of the flies in all of the cages had died.
Mating. We placed one virgin female, one control male, and
one treated male in each of 100 glass vials for each dosage of each
substance,. Half of the treated males and half of the control males
were marked with a black marker at the distal end of their right
wing. In the 100 vials that contained only control flies, we marked
one of the males.
We gave the flies two hours in which to mate. A successful mating
event was scored when a malemounted on a femalefor thirty seconds
ormore.We recorded whichmalewassuccessfuland whetherhe was
marked, unmarked, treated, or control for each vial. We conducted
mating assays after five days of cage life and again after three weeks.
Fecundity. For each dosage of each substance, and the
controls, we set up 80 vials, one quarter full of charcoal agar
media, containing one treated female and one treated male (or
untreated in the case of the controls). The number of eggs laid
after one day in the vials were counted and recorded.
We counted and recorded the number of eggs laid by the flies in
each of 20 vials for each cage, 80 for each dose, after one day spent
in the charcoal vials. We also conducted fecundity assays at five
days of cage life and again at three weeks.
Statistical Analysis
Gompertz mortality. In this formulation we will let the
index i indicate one of the 20 cages, j indicates drug treatment
(0=control, 1=0.1, 2=1.0 drug, and 3=10 drug), and t indicates
age. Then the predicted mortality between ages t and t+1i syijt.
The basic nonlinear model is given by,
yijt~f Yij,t
  
zeijt, ð1Þ
where Yij is the vector of parameters, and eijt is the within
population variation. The function f is the Gompertz model,
1{
pijtz1
pijt
, ð2Þ
where
pijt~exp
Aij
aij
1{exp aijt
        
: ð3Þ
The parameter A is sometimes called the age-independent
parameter of the Gompertz and is a reflection of background mortality
that does not change with age. On the other hand a is called the age-
dependent parameter and measures the rate at which mortality
increases with age, e.g. senescence. We assume that the parameters of
the Gompertz equation may be affected by the fixed drug treatment
effect, the fixed initial cage density (Nij), and the random cage
environment. These assumptions translate into a system of equations,
Aij~b1zc11d1jzc12d2jzc13d3jzc14d4jzp1Nijzb1i
aij~b2zc21d1jzc22d2jzc23d3jzc24d4jzp2Nijzb2i,
ð4Þ
where dlm~
1 if l~m
0 otherwise
 
. To test for significant effects of drugs on
A and a corresponds to a test for whether c1j or c2j is significantly
different from zero [33]. The effects of different densities on A and a
are assessed by the parameters p1 and p2 respectively.
The variance of mortality is expected to change with the mean
value of mortality. The general formulation for the variance of eijt
is,
Var eijt
  
%s2g2 ^ u uijt
  
, ð5Þ
where ^ u uijt~Ey ijtjbi
  
. In this analysis we used g(.)=| yijt|
d where d
is estimated from the data. The bi were distributed as,
bi*N 0,
s1 0
0 s2
     
: ð6Þ
The maximum likelihood procedure would not converge when
the entire valproic acid data set was run. Accordingly, we have
analyzed each drug dose and control separately in table 2.
Demography of B and O populations. For each of the five
B and five O populations, four cages were used to estimate
longevity and mortality rates. Each of these cages had
approximately 750 individuals per sex. We are ultimately
interested in differences between the B and O populations, as
well as the variation in demography that can be attributed to the
replicate cages and to the replicate populations within the same
selection treatment, e.g. B or O. Below we describe how we
estimated the demographic parameters for each cage-sex
population. From these 80 populations (4 cages62 sexes610
populations) we estimated variation for demographic traits and
tested for significant differences between B and O populations.
We used a Gompertz model to study mortality rates [23]. This
model shows exponentially increasing mortality rates at all ages. Age-
specific mortality rates were modeled by the continuous-time
Gompertz equation or Aexp(ax), where A is the age-independent
rateofmortalityandais the age-dependent rate of mortality increase.
The parameters A and a were estimated by maximum likelihood.
The likelihood function was constructed from ages at death of
the N members of a cohort following methods similar to Mueller et
al. [23]. In this experiment cages were checked every day. Thus,
the raw data consists of the number of dead flies recorded every
day, which might be zero. We number the daily checks
sequentially and let the tN be the last check during which the
last fly died. Then the number of dead flies in each daily period is,
d1,d2,...,dtN:
Likewise the number of flies alive at the start of each census
period is N1 (=N), N2,… ,NtN ~dtN ðÞ . Let q(i) be the probability
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period i+1. Then the likelihood function is defined as,
L~ P
i~tN
i~1
Ni
di
  
qi ðÞ
di 1{qi ðÞ ðÞ
Ni{di ðÞ : ð7Þ
The q(i) were then estimated as,
1{exp
A exp(ai){exp(a(iz1)) ½ 
a
  
: ð8Þ
Female Fecundity. Female fecundity may be affected by age
and drug dose. We tested this we a linear model which estimated
both the effects of each drug, age and the interaction between age
anddrugdose.Thislinearmodelprovidesestimatesofthemagnitude
of the effects of each drug and their statistical significance. Let fijk
be the number of eggs laid by the ith female receiving drug treatment
j (0=control, 1=0.1 drug dose, 2=1.0 drug dose, and 3=10 drug
dose), and age k (1=young, 2=old). Since the numbers of eggs are
very different between young and old and between some of the
drug treatments, we modeled the square root of fijk to make the
variance less variable. The final model used was,
ﬃﬃﬃﬃﬃﬃ
fijk
p
~cza1d1jza2d2jza3d3jzkd2k
zb1d1jd2kzb2d2jd2kzb3d3jd2kzsijk,
ð9Þ
where dlm~
1 if l~m
0 otherwise
 
. To test for significant effects of drugs on
fijk corresponds to a test for whether aj is significantly different from
zero. Similar tests on k indicate whether there are age-specific effects
on fecundity and tests on bj test for drug by age interactions.
Mating Preference. In this study, females were given a
choice of two males to mate with. If females did not mate the
experiment was discarded. Males were classified as (i) mated or not
mated, (ii) marked or not marked, (iii) young or old, and (iv)
drugged or controls. The counts of males in each of the possible
cells from this experiment can then be analyzed by log linear
hierarchical models [34]. Marking was necessary to distinguish
drugged males from controls. However, since it may impact the
females’ preference we have controlled for this in two ways. In the
mating assay, half of the controls males and half of the drugged
males were marked. Therefore, we can directly test in each
experiment if mating status is independent of marking status. In
addition we have also competed control males against themselves
with one male marked and a second male unmarked.
We consider the experiment with controls only first. We
numerically identify the classification variables as mating status-1,
marked status-2, and age-3. If we model the counts in each cell as
simply the sum of each log of the probabilities of each factor, the
appropriate statistical model is C1+C2+C3. The model term C12
indicates the sum of a two-way interaction between mating status
and marked status (C1:2) as well as the separate factors C1 and C2,
i.e. C1:2+C1+C2. Models are tested by taking the difference of the
likelihood ratio, or G
2 statistic [34], of each model. This difference
has a chi-squared distribution and the degrees of freedom are
calculated as the difference between the degrees of freedom of the
two models. Thus, a test of marking status on mating status would
correspond to a test of the model with the interaction of marking
and mating status (C12+C3) to the sub-model without this
interaction (C1+C2+C3).
Experiments with drugged males have three questions of
interest: (i) is mating status independent of drugged status, (ii) is
mating status independent of marking status, and (iii) does age
affect the mating status by drugged status interaction. This last
hypothesis concerned whether female preference for drugged
versus undrugged males changes with age. We use the same
numerical labels as above, except now drug status is indicated by
numerical index 4. To test hypothesis (i), we compare the model
with a mating status by drug status interaction, C14+C2+C3, to one
without, C1+C2+C3+C4. To test hypothesis (ii), the effect of
marking on mating status, we compare the model with a mating
status by making status interaction, C12+C3+C4, to a model without
the interaction, C1+C2+C3+C4. To test hypothesis (iii), the possible
effect of age on mate choice, we compare the model with the three
way interaction between mating status, drug status and age,
C1:2:3+C14+C2+C3, to the model without the three way interaction,
C14+C2+C3.
Software. All statistical analyses were carried out with R
(version 2.7.0 and 2.7.1, The R Foundation for Statistical
Computing). The Gompertz analysis of the supplements used
the non-linear, mixed effects R program (nlme R-package). The
fecundity results were analyzed with the linear model function (lm)
of R. The log-linear analysis of male mating was analyzed with the
loglm R-function (MASS R-package). The Gompertz utilized R-
code used the optim R-function for finding maxima of the
likelihood function.
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